tbuckley/cabot-search huggingface dataset:
Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism
Authors: Bakhtawar K. Mahmoodi, Mary Cushman, Inger Anne Næss, Matthew A. Allison, Willem Jan Bos, Sigrid K. Brækkan, Suzanne C. Cannegieter, Ron T. Gansevoort, Philimon N. Gona, Jens Hammerstrøm, John-Bjarne Hansen, Susan Heckbert, Anders G. Holst, Susan G. Lakoski, Pamela L. Lutsey, JoAnn E. Manson, Lisa W. Martin, Kunihiro Matsushita, Karina Meijer, Kim Overvad, Eva Prescott, Marja Puurunen, Jacques E. Rossouw, Yingying Sang, Marianne T. Severinsen, Jur ten Berg, Aaron R. Folsom, Neil A. Zakai
Journal: Circulation (2016)

Much controversy surrounds the association of traditional cardiovascular disease risk factors with venous thromboembolism (VTE).We performed an individual level random-effect meta-analysis including 9 prospective studies with measured baseline cardiovascular disease risk factors and validated VTE events. Definitions were harmonized across studies. Traditional cardiovascular disease risk factors were modeled categorically and continuously using restricted cubic splines. Estimates were obtained for overall VTE, provoked VTE (ie, VTE occurring in the presence of 1 or more established VTE risk factors), and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.The studies included 244 865 participants with 4910 VTE events occurring during a mean follow-up of 4.7 to 19.7 years per study. Age, sex, and body mass index-adjusted hazard ratios for overall VTE were 0.98 (95% confidence interval [CI]: 0.89-1.07) for hypertension, 0.97 (95% CI: 0.88-1.08) for hyperlipidemia, 1.01 (95% CI: 0.89-1.15) for diabetes mellitus, and 1.19 (95% CI: 1.08-1.32) for current smoking. After full adjustment, these estimates were numerically similar. When modeled continuously, an inverse association was observed for systolic blood pressure (hazard ratio=0.79 [95% CI: 0.68-0.92] at systolic blood pressure 160 vs 110 mm Hg) but not for diastolic blood pressure or lipid measures with VTE. An important finding from VTE subtype analyses was that cigarette smoking was associated with provoked but not unprovoked VTE. Fully adjusted hazard ratios for the associations of current smoking with provoked and unprovoked VTE were 1.36 (95% CI: 1.22-1.52) and 1.08 (95% CI: 0.90-1.29), respectively.Except for the association between cigarette smoking and provoked VTE, which is potentially mediated through comorbid conditions such as cancer, the modifiable traditional cardiovascular disease risk factors are not associated with increased VTE risk. Higher systolic blood pressure showed an inverse association with VTE.
Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage
Authors: Chris L. Pashos, Brian GM Durie, Robert Rifkin, Howard Terebelo, Cristina Gasparetto, Jayesh Mehta, Kathleen Toomey, Rafat Abonour, Rafael Fonseca, Mohit Narang, Jatin J Shah, Arlene S Swern, Kristen A Sullivan, Thomas K. Street, Zeba M. Khan
Journal: Blood (2011)
Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma
Authors: Patricia Maiso, AbdelKareem Azab, Yang Liu, Yong Zhang, Feda Azab, Antonio Sacco, Hai T Ngo, Yi Liu, Brittany Morgan, Christian Rommel, Kenneth C. Anderson, Aldo M. Roccaro, Irene M. Ghobrial
Journal: Blood (2010)
Low Levels of Mir-151-5p and Mir-451 Predict Relapse in Pediatric B-Lineage Acute Lymphoblastic Leukemia.
Authors: Smadar Avigad, Iedan RN Verly, Gertjan J.L. Kaspers, Jacqueline Cloos, Anat Ohali, Michal Hameiri-Grossman, Eva Fonkova, Jan Trka, Drorit Luria, Yona Kodman, Hadar Mirsky, Dafna Gaash, Marta Jeison, Galia Avrahami, Sarah Elitzur, Gil Gilad, Batia Stark, Isaac Yaniv
Journal: Blood (2012)
Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.
Authors: Michael C O'Dwyer, Emma Kent, Michael Parker, Ronan T. Swords, Frank Giles, Philipp le Coutre, Swaminathan Padmanabhan, Brian Moulton, Mary Frances McMullin, Stephen Langabeer, Karine Egan, Eibhlin Conneally
Journal: Blood (2009)
The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis
Authors: Sandy W. Wong, Giovanni Palladini, Ute Hegenbart, Heather Landau, Melissa Warner, Arnaud Jaccard, Herve Avet-Loiseau, Timon Hansen, Joan Bladé, María Teresa Cibeira, Efstathios Kastritis, Stefan Schönland, Raymond L. Comenzo
Journal: Blood (2015)
Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy
Authors: Meike Adam, Pierre Tennstedt, Dominik Lanwehr, Derya Tilki, Thomas Steuber, Burkhard Beyer, Imke Thederan, Hans Heinzer, Alexander Haese, Georg Salomon, Lars Budäus, Uwe Michl, Dirk Pehrke, Pär Stattin, Jürgen Bernard, Bernd Klaus, Raisa S. Pompe, Cordula Petersen, Hartwig Huland, Markus Graefen, Rudolf Schwarz, Wolfgang Huber, Stacy Loeb, Thorsten Schlomm
Journal: European Urology (2016)
Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo
Authors: Barbara Muz, Joseph Abraham, Feda Azab, Pilar De La Puente, Nicholas Potter, Benjamin Minch, Farideh Ordikhani, Noha Salama, Abdel Kareem Azab
Journal: Blood (2015)
The Case | Unexplained fever and acute kidney injury in a kidney transplant patient
Authors: Flávio J. Paula, Precil D.M.M. Neves, Carolina S. Lazari, Rafael G. Ramos, Marcella M. Frediani, Marcelo V.A. Silva, Nzuzi Mfinda, Lígia C. Pierrotti, Daísa S.R. David, Leonardo A. Testagrossa, Elias David-Neto
Journal: Kidney International (2016)
PTH-106 Outcomes of Screening for Hepatitis B Virus During Pregnancy
Authors: MN Rahim, G Bird
Journal: Gut (2016)

<h3>Introduction</h3> Chronic hepatitis B (HBV) is a major cause of liver disease worldwide. It is estimated 0.4% of pregnant women in England have hepatitis B. The UK pregnancy screening programme includes hepatitis B and has an uptake of 97%. Infants born to hepatitis B infected mothers are at risk of perinatal transmission and it is important to identify those requiring antiviral treatment in the third trimester in order to reduce this risk. National policy recommends immunisation of infants, with vaccine +/- immunoglobulin. NICE guidance suggests that all hepatitis B positive pregnant women should be assessed by a specialist within 6 weeks. Approximately 5000 babies are born at Maidstone and Tunbridge Wells annually and mothers found to have HBV at pregnancy screening are referred to GB. The objectives of this study were to identify the demographics of patients in the antenatal screening clincis and associated outcomes in terms of further management and maternal case management. <h3>Methods</h3> Between 2005 and 2015, 33 mothers were identified as having hepatitis surface antigen (HBsAg) positivity. The mothers were identified through two separate databases held by GB and the antenatal screening midwife. Data was obtained retrospectively from patient, laboratory and imaging records. These included age, ethnicity, date of HBsAg positivity, new or known diagnosis, interval to Hepatology clinic review and "did not attend" rate. The HBV serological profile, history of antiviral treatment and subsequent follow up were determined. <h3>Results</h3> The predominant ethnicities in this cohort of hepatitis B positive mothers were Eastern European (27%) and African (24%). Of the 33 mothers, 45% did not volunteer a known diagnosis of hepatitis B until identification at screening, 27% received a new diagnosis through screening and it remained unclear whether the remaining 27% knew about their diagnosis or not. 42% of patients were seen in Hepatology clinic within 6 weeks of referral. 15% of mothers did not attend their first clinic appointment and as a result 80% of these did not have HBV DNA checked during or after pregnancy. The only eligible patient for treatment did not attend her appointment to initiate therapy. Vaccination of new born babies was 100%, and two also received immunoglobulins. After delivery, 39% did not attend their follow up appointments. <h3>Conclusion</h3> The majority of HBV positive mothers were born outside the UK, with the largest group from Eastern Europe. There was considerable clinic non-attendance both at initial appointment and more strikingly post-delivery. The disappointing rates of patient engagement in the Hepatology clinic are perhaps due to the language barrier or cultural considerations. Areas to improve the service might include better use of interpreters, counselling and educational materials. <h3>Disclosure of Interest</h3> None Declared
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients
Authors: C. Michael Gibson, Gerald Chi, Rim Halaby, Serge Korjian, Yazan Daaboul, Purva Jain, Douglas Arbetter, Samuel Z. Goldhaber, Russel Hull, Adrian F. Hernandez, Alex Gold, Olga Bandman, Robert A. Harrington, Alexander T. Cohen
Journal: Circulation (2016)

Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).Hospitalized acutely medically ill subjects (n=7513) were randomized in a double-dummy double-blind fashion to either extended-duration oral betrixaban (80 mg once daily for 35-42 days) or standard-dose subcutaneous enoxaparin (40 mg once daily for 10±4 days) for venous thromboprophylaxis. Stroke events were adjudicated by an independent, blinded event adjudication committee.The mean age of study participants was 76 years; 45% were male; 13% had had a stroke; and 45% had congestive heart failure. There were fewer all-cause strokes (0.54% versus 0.97%; relative risk [RR]=0.56; 95% confidence interval, 0.32-0.96; P=0.032; adjusted RR=0.43%; number needed to treat=233) and ischemic strokes (0.48% versus 0.91%; RR=0.53; 95% confidence interval, 0.30-0.94; P=0.026; adjusted RR=0.43%; number needed to treat=233) among patients treated with betrixaban versus enoxaparin through 77 days of follow-up. Among high-risk subjects, those with congestive heart failure or ischemic stroke as their index event, betrixaban reduced the risk of all-cause stroke (0.72% versus 1.48%; RR=0.49; 95% confidence interval, 0.26-0.90; P=0.019; adjusted RR=0.76%; number needed to treat=132) and ischemic stroke (0.63% versus 1.38%; RR=0.45; 95% confidence interval, 0.24-0.87; P=0.014; adjusted RR=0.75%; number needed to treat=134) compared with enoxaparin.Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01583218.
Differential down Regulation of Inflammatory Cytokines, CRP, CD 40-L, MCP-1 and NO Levels in Malignancy Associated Thrombosis by Extended Treatment of Enoxaparin and Warfarin.
Authors: Jawed Fareed, Debra A. Hoppensteadt, Susannah Cort, Omer Iqbal, Peter Bacher, Daniel Fareed, Michelle Florian, Steven Deitcher
Journal: Blood (2004)
Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD
Authors: Joseph M. Connors, Paul Klimo, Grenfell Adams, Bruce F. Burns, Ian Cooper, Ralph M. Meyer, Susan E. O'Reilly, Joseph Pater, Ian Quirt, Anna Sadura, Chaim Shustik, Jamey Skillings, Simon Sutcliffe, Shailendra Verma, Sam Yoshida, Benny Zee
Journal: Journal of Clinical Oncology (1997)

The institution affiliation section on page 1638 of the April 1997 article entitled, "Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD: A Report From the National Cancer Institute of Canada Clinical Trials Group" by Connors, et al (J Clin Oncol 15:1638–1645, 1997) was incomplete. The "London Regional Cancer Centre, London, Ontario, Canada" should have been included in the listing of author-affiliated institutions.
SP0189 Why Choose Random Effects Models for Longitudinal Datasets?
Authors: S. Norton
Journal: Annals of the Rheumatic Diseases (2016)

Longitudinal data, where there are multiple repeated observations of an outcome variable for each individual, requires appropriate analysis to account for the non-independence of observations within individuals. A variety of methods are available, including random-effects (aka multi-level or mixed) models and marginal (GEE) models. Random-effects models, the focus of this presentation, extend the standard regression model to allow for subject-specific estimates of the baseline level of the outcome variable (random intercepts) and its rate of change over time (random slopes). Under certain circumstances both random-effects and marginal model approaches give equivalent estimates. However, in many situations they will not and it can be difficult to decide whether one approach should be favoured over the other. This presentation will provide an introduction to the random-effects model for longitudinal data using data from the Early Rheumatoid Arthritis Study. Particular strengths of random-effects models such as how missing data on outcome variables at some assessments are handled and the clustering of individuals within hospitals will be considered. Furthermore, differences in the interpretation of coefficients between random-effects and marginal models where the outcome variable is dichotomous will be discussed, with guidance on situations where each approach is more useful. <h3>Disclosure of Interest</h3> None declared
Edward Walter Leslie Fletcher
Authors: John Dyet, Victoria Oliver
Journal: BMJ (2016)

Edward Walter Leslie Fletcher—known to friends and colleagues as “Wattie”—was a kind, considerate, and mild mannered man. Although he was ambitious and driven for causes close to his heart, he was always the perfect gentleman. He will be remembered for his association with the founding of Green College, Oxford, and his major role in the formation of the British Society of Interventional Radiology.

Wattie’s father, Leslie Fletcher, was a GP and came from a large medical family (Leslie’s father and five brothers were all doctors in Cumbria). Leslie joined up at the outbreak of war in 1939 and he was sent to York to receive wounded soldiers. His wife later joined him there. Wattie was sent to live with an old lady in Brassington, a small hilltop village. He went to public school in Repton, where he made lifelong friends and became a fine athlete as a runner, hurdler, and cross country runner. In 1953 Wattie went up to Cambridge to read medicine and geology as a half subject at Emmanuel College. He had a lifelong passion for rocks and fossils and a great love of the outdoors, walking and climbing in the Lake District and Peak District. In 1956 he went to St Thomas’ Hospital in London. At his final examinations in 1959 he was awarded the All England Hancock prize for surgery.

In 1960, as part of his house …
FRI0281 MRI versus 18F-FDG Pet in Inflammatory Myopathies and Fasciitis
Authors: H. Petit, A. Meyer, F. Hubele, G. Bierry
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Idiopathic inflammatory myopathies (IIM) and eosinophilic fasciitis (EF) are defined as idiopathic inflammation of muscle or fascia. In patients clinically suspected of having those entities, Magnetic Resonance Imaging (MRI) is performed to assess muscle involvement, and 18F- Fluorodeoxyglucose Positron Emission Tomography (PET) to exclude a paraneoplastic origin of the symptoms. <h3>Objectives</h3> In this study, we aimed to compare the relative performance of MRI and PET in the detection of muscle and/or fascia inflammation. <h3>Methods</h3> This retrospective board – approved study included 18 patients suspected of MII (12) or EF (6) in which both MRI and an <sup>18</sup>F-FDG PET were available and performed within a interval ≤3 months, and in which no therapeutic changes occurred between the two exams. The mean interval between MR and PET was 7 days [range -62 (PET performed between MRI) to +91]. For each subject, muscular involvement was independently evaluated on MRI and PET in up to 17 possible predefined muscular groups, subdivided on 3 categories: upper limbs, lower limbs and trunk. A total of 220 corresponding muscular groups were analyzed. A group was considered abnormal on MR when a high signal was seen on fat saturated T2w images (either in muscle or fascia) and, on PET, when high uptake was present. The Kappa statistics between the two imaging modalities were calculated. <h3>Results</h3> MRI detected significantly more lesions than <sup>18</sup>F-FDG PET in the 3 categories (upper limbs, lower limbs and trunk) (p&lt;0.001). The overall agreement between MRI and <sup>18</sup>F-FDG PET was 0.67 (95% confidence interval 0.57 to 0.77); it was 0.81 (CI 95 0.70–0.93), 0.50 (CI 95 0.31–0.68) and 0.65 (CI 95 0.34–0.97) for upper limbs, lower limbs and trunk, respectively. <h3>Conclusions</h3> MRI seems more accurate to detect inflammatory changes of muscle or fascia than 18FDG PET when myositis or fasciitis is clinically suspected. <h3>Disclosure of Interest</h3> None declared
Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial
Authors: Michael Lubbert, Claudia Schmoor, Björn Rüter, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Rainer Claus, Barbara Deschler, Björn W. Hackanson, Konstanze Döhner, Pierre Wijermans, Hartmut Döhner
Journal: Blood (2010)
Dysregulated Expression of Myeloid Nuclear Differentiation Antigen (MNDA) in MDS: Possible Role in TRAIL-Induced Apoptosis.
Authors: Robert C. Briggs, Keith Shults, Leanne Flye, Sara A. McClintock-Treep, Madan H. Jagasia, Stacey A. Goodman, Fouad I. Boulos, James W. Jacobberger, Greg Stelzer, David R. Head
Journal: Blood (2005)
Correlation Between c-MYC Gene Expression and Response after Induction Therapy Among Patients with Newly Diagnosed Multiple Myeloma and Monoclonal Gammopathy Undetermined Significance
Authors: Maria Nareyko, Larisa P. Mendeleeva, Vadim Surin, Ekaterina Demidova, Olga S. Pokrovskaya, Larisa A. Kuzmina, Elena Gribanova, Vyacheslav Rizhko, Irina Galtseva, Evdokia S. Urnova, Mihail Drokov, Maia Firsova, Maksim Solovev, Eleonora Boeva, Olga Koroleva, Islam Nakastoev, Aleksander Grachev, Madina Kanaeva, Anjelika Danilina, Elena N. Parovichnikova, Valeri G. Savchenko
Journal: Blood (2015)
Zebrafish Growth Factor Independence Transcription Factors Establish a New Paradigm for Regulation of Primitive and Definitive Hematopoietic Lineages,
Authors: Jeffrey D. Cooney, Ebrahim Shafizadeh, Paul F. McBride, Kelli J. Carroll, Heidi Anderson, Jared J. Ganis, Trista E. North, Barry H. Paw
Journal: Blood (2011)
Hereditary Thrombocytosis Caused By a Novel Germ-Line Mutation In The Gelsolin Gene
Authors: Annalisa Pianta, Kun Liu, Pontus Lundberg, Takafumi Shimizu, Hui Hao-Shen, Stephan Dirnhofer, Robert Kralovics, Amy D. Shapiro, Radek C. Skoda
Journal: Blood (2013)
Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin
Authors: Nora V. Butta, M T Alvarez Román, Ihosvany Fernández Bello, Elena Arias-Salgado, Raquel de Paz, Isabel Rivas Pollmar, Mónica Martín Salces, Miguel Canales, Victor Jimenez Yuste
Journal: Blood (2014)
SP0072 The Role of Health Professionals in Improving Shared Decision Making with Young People with RMDS
Authors: A. Alunno
Journal: Annals of the Rheumatic Diseases (2016)

In the past, physician-patient relationship was mostly unilateral and disease-centered as the physician made all the disease-related decisions on behalf of the patients. Nowadays, based on different cultural and legal aspects, the physician-patient relationship relies on the shared decision making (SDM) process. SDM is the approach where health professionals and patients decide the best approach on disease-related decisions. In this process, patients receive from clinicians and health professionals other than medical doctors the support and all relevant information to analyze the different available options and to identify their preferences in terms of tests, treatments and daily management of the disease. In this context, SDM has a positive impact in clinical practice allowing the integration of the physician9s point of view with the patients9 perspective. The main target of SDM is to achieve the most effective, most satisfactory and best tolerated approach to optimize diagnostic, therapeutic and overall management strategies through: i. patients9 awareness and attitude towards the disease, ii. patients9 self-confidence, iii. tailored therapy, iv. therapy adherence, v. informed decision regarding disease-related daily life issues. In the field of rheumatic and musculoskeletal diseases (RMDs), the SDM process requires a multidisciplinary team involving not only rheumatologists but also other specialists and health care professionals, other than medical doctors, specialized in rheumatology. However, the multidisciplinary team pursuing this patient-centered approach, should be guided by the rheumatologist that has the widest point of view regarding all possible aspects of the disease. Such multidisciplinary approach ensures that patients are fully aware of all aspects of the disease, of how their life may be affected and, most importantly, of how to manage different situations. Patients with distinct RMDs suffer from different complaints and require different treaments according to the diagnosis. Moreover, it is well established that young people with RMDs have different priorities and needs compared to adult patients. Finally, subjects included in different age ranges within young patients are further different from each other. This requires an additional effort of the multidisciplinary team to tailor the support to specific circumstances. Self-confidence, working disability as well as social life, family life and intimacy represent some of the domains mostly affected in young patients with RMDs. Therefore, the interaction of rheumatologists, other specialists, and health professionals specialized in rheumatology is compelling to optimize the management as well as the SDM process with young patients with RMDs. In conclusion, empowering young patients with RMDs to know and manage their own condition is crucial for long-term improvement of their quality of life and should be thoroughly applied in clinical practice. <h3>Disclosure of Interest</h3> None declared
Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.
Authors: Zhengshan Chen, Huimin Geng, Lars Klemm, Maike Buchner, Kaveh Hemati, Seyedmehdi Shojaee, Warren S. Alexander, William L. Carroll, Cheryl L Willman, Markus Muschen
Journal: Blood (2012)
Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia
Authors: C Cerella, A Gaigneaux, A Mazumder, J-Y Lee, E Saland, F Radogna, T Farge, F Vergez, C Récher, J-E Sarry, K-W Kim, H Y Shin, M Dicato, M Diederich
Journal: Leukemia (2016)

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia
Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES)
Authors: Nanja van Geel, Janny E. Lommerts, Marcel W. Bekkenk, Cecilia A.C. Prinsen, Viktoria Eleftheriadou, Alain Taieb, Mauro Picardo, Khaled Ezzedine, Albert Wolkerstorfer, Reinhart Speeckaert
Journal: Journal of the American Academy of Dermatology (2016)